Publication: Tumor heterogeneity: morphological,
molecular and clinical implications
Loading...
Date
2000
Authors
Lleonart, M. E. ; Martin-Duque, P. ; Sanchez-Prieto, R. ; Moreno, A. ; Ramon y Cajal, S.
item.page.secondaryauthor
item.page.director
Publisher
F. Hernández y Juan F. Madrid. Universidad de Murcia: Departamento de Biología Celular e Histología
publication.page.editor
publication.page.department
DOI
item.page.type
info:eu-repo/semantics/article
Description
Abstract
Malignant tumors are characterized by their
great heterogeneity and variability. There are hundreds
of different types of malignant tumors that harbour many
oncogenic alterations. The tumor heterogeneity has
important morphological, molecular and clinical
implications. Except for some hematopoietic and
lymphoproliferative processes and small cell infant
tumors, there are not specific molecular alterations for
most human tumors. In this review we summarize the
most important aspects of carcinogenesis and chemoradiosensitivity of malignant cells. In this regard, some
oncogenes such as neu , ras and bcl-2 have been
associated with cellular resistance to treatment with
anticancer agents. The knowledge of oncogenic
alterations involved in each tumor can be important to
correlate the morphological features, the genetic
background, the prognosis and the clinical response to
treatment with anticancer agents. Based on the molecular
background of the tumor there are new cancer gene
therapy protocols. For example using adenovirus Ela in
tumors with overexpression of neu oncogene, inhibitors
of tirosine kinase specific for the PDGF receptor in
glioma, inhibitors of farnesil transferase to prevent ras
activity in tumors with mutations in the ras gene.
publication.page.subject
Citation
item.page.embargo
Ir a Estadísticas
Este ítem está sujeto a una licencia Creative Commons. CC BY 4.0